MX336347B - Metodo para atenuar los efectos adversos del farmaco usando los acidos grasos omega-3 como un vehiculo terapeutico parenteral del farmaco. - Google Patents

Metodo para atenuar los efectos adversos del farmaco usando los acidos grasos omega-3 como un vehiculo terapeutico parenteral del farmaco.

Info

Publication number
MX336347B
MX336347B MX2013002725A MX2013002725A MX336347B MX 336347 B MX336347 B MX 336347B MX 2013002725 A MX2013002725 A MX 2013002725A MX 2013002725 A MX2013002725 A MX 2013002725A MX 336347 B MX336347 B MX 336347B
Authority
MX
Mexico
Prior art keywords
omega
fatty acids
events
parenteral therapeutic
drug
Prior art date
Application number
MX2013002725A
Other languages
English (en)
Other versions
MX2013002725A (es
Inventor
David F Driscoll
Original Assignee
Stable Solutions Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stable Solutions Llc filed Critical Stable Solutions Llc
Publication of MX2013002725A publication Critical patent/MX2013002725A/es
Publication of MX336347B publication Critical patent/MX336347B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un método para administrar parenteralmente una composición, el método incluye administrar parenteralmente a una persona una composición que incluye por lo menos un ácido graso omega-3 y por lo menos un fármaco, donde por lo menos una fuente de ácido graso omega-3 y por lo menos un fármaco se administran simultáneamente.
MX2013002725A 2010-09-10 2011-09-12 Metodo para atenuar los efectos adversos del farmaco usando los acidos grasos omega-3 como un vehiculo terapeutico parenteral del farmaco. MX336347B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/923,257 US20110071090A1 (en) 2009-03-11 2010-09-10 Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
PCT/US2011/001567 WO2012033538A1 (en) 2010-09-10 2011-09-12 Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle

Publications (2)

Publication Number Publication Date
MX2013002725A MX2013002725A (es) 2013-04-08
MX336347B true MX336347B (es) 2016-01-15

Family

ID=44675802

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002725A MX336347B (es) 2010-09-10 2011-09-12 Metodo para atenuar los efectos adversos del farmaco usando los acidos grasos omega-3 como un vehiculo terapeutico parenteral del farmaco.

Country Status (15)

Country Link
US (1) US20110071090A1 (es)
EP (1) EP2613809B1 (es)
JP (1) JP6000251B2 (es)
KR (1) KR101923192B1 (es)
CN (1) CN103200965B (es)
BR (1) BR112013004440B1 (es)
CA (1) CA2808406C (es)
ES (1) ES2760997T3 (es)
IL (1) IL223955A (es)
MX (1) MX336347B (es)
PL (1) PL2613809T3 (es)
PT (1) PT2613809T (es)
RU (2) RU2013115923A (es)
TW (1) TWI505837B (es)
WO (1) WO2012033538A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034389B2 (en) 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US8993625B2 (en) 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
US10052352B2 (en) 2011-06-15 2018-08-21 Stable Solutions Llc Therapeutic application of parenteral krill oil
CN107648268B (zh) * 2011-06-15 2021-06-22 稳定解决方案有限责任公司 磷虾油的胃肠外治疗应用
ES2741560T3 (es) * 2012-03-30 2020-02-11 Micelle Biopharma Inc Composiciones de ésteres de ácidos grasos omega-3
NZ702325A (en) 2012-05-10 2016-09-30 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
WO2013192109A1 (en) * 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
CN103054799B (zh) * 2012-10-11 2015-04-08 北京泰德制药股份有限公司 一种盐酸胺碘酮注射乳剂及其制备方法
KR20210059779A (ko) * 2012-12-06 2021-05-25 마티나스 바이오파마, 인코포레이티드 오메가-3 펜타엔산 조성물 및 사용 방법
WO2014143272A1 (en) * 2013-03-13 2014-09-18 Matinas Biopharma Inc. Omega-3 pentaenoic acid compositions and methods of use
US10143674B2 (en) * 2014-01-28 2018-12-04 Fresenius Kabi Deutschland Gmbh Composition comprising EPA and DHA triglycerides for parenteral administration
WO2015113986A1 (en) * 2014-01-28 2015-08-06 Fresenius Kabi Deutschland Gmbh Composition comprising epa and dha ethylester for parenteral administration
WO2017041094A1 (en) 2015-09-03 2017-03-09 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-hdha and 18- hepe and methods of using same
EP3525781B2 (en) 2016-10-11 2024-04-24 Fresenius Kabi Deutschland GmbH Composition comprising epa and dha for an enhanced efficacy of anticancer agents
WO2018088689A1 (ko) * 2016-11-08 2018-05-17 차의과학대학교 산학협력단 비스테로이드 항염증제의 부작용 방지용 조성물 및 부작용이 나타나지 않은 항염용 조성물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118493A (en) * 1986-05-02 1992-06-02 Brigham And Women's Hospital Composition having reduced nephrotoxocity comprising a fatty acid containing component and cyclosporine
DE3734147C2 (de) * 1987-10-09 1998-10-29 Braun Melsungen Ag Isotone omega-3-fettsäurenhaltige Fettemulsion und ihre Verwendung
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5780451A (en) * 1994-04-01 1998-07-14 Abbott Laboratories Nutritional product for a person having ulcerative colitis
US5574065A (en) * 1994-04-21 1996-11-12 Clintec Nutrition Co. Method and composition for normalizing injury response
KR100293297B1 (ko) * 1995-11-24 2001-08-07 씨.지. 온닝크 어유기재조성물
DE69625616T3 (de) * 1995-11-28 2010-07-08 B. Braun Melsungen Ag Lipidemulsionen mit optimierter hydrolyse sowie deren verwendung
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
DE69842121D1 (de) * 1997-12-10 2011-03-17 Cyclosporine Therapeutics Ltd Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen
IT1304406B1 (it) * 1998-10-21 2001-03-19 Danital Italia S R L Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3.
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6380253B1 (en) * 2000-01-05 2002-04-30 Efa Sciences Llc Method of stabilizing and potentiating the action of anti-angiogenic substances
GB0012597D0 (en) * 2000-05-25 2000-07-12 Astrazeneca Ab Formulation
EP1539104A2 (en) * 2000-12-29 2005-06-15 The Trustees Of Columbia University In The City Of New York Use of iv emulsions with different triglyceride composition, particle size and apolipoprotein e for targeted tissue delivery of hydrophobic compounds
EP1279400A1 (en) * 2001-07-25 2003-01-29 Target Hit sa Modifying the fatty acid composition of cell membranes of organs and tissues
JP2006507309A (ja) * 2002-10-31 2006-03-02 アルザ・コーポレーシヨン 疎水性薬剤の上昇した生物学的利用性を提供する製剤
US7323206B1 (en) * 2003-03-04 2008-01-29 B. Braun Medical Inc. Reagents and methods for all-in-one total parenteral nutrition for neonates and infants
WO2005046669A1 (en) * 2003-11-12 2005-05-26 Children's Medical Center Corporation Treatment and prevention of liver disease associated with parenteral nutrition (pn)
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
WO2008036353A2 (en) * 2006-09-19 2008-03-27 The Trustees Of Columbia University In The City Of New York Omega-3 diglyceride emulsions
US8241672B2 (en) * 2009-03-11 2012-08-14 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US8993625B2 (en) * 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle

Also Published As

Publication number Publication date
MX2013002725A (es) 2013-04-08
PL2613809T3 (pl) 2020-01-31
EP2613809B1 (en) 2019-07-24
CN103200965A (zh) 2013-07-10
WO2012033538A1 (en) 2012-03-15
US20110071090A1 (en) 2011-03-24
BR112013004440B1 (pt) 2021-02-09
KR20130135839A (ko) 2013-12-11
RU2017126315A (ru) 2019-01-31
JP2013537192A (ja) 2013-09-30
IL223955A (en) 2016-02-29
RU2017126315A3 (es) 2020-10-30
PT2613809T (pt) 2019-10-18
EP2613809A1 (en) 2013-07-17
TWI505837B (zh) 2015-11-01
TW201219057A (en) 2012-05-16
CA2808406A1 (en) 2012-03-15
KR101923192B1 (ko) 2018-11-28
ES2760997T3 (es) 2020-05-18
CA2808406C (en) 2021-03-16
JP6000251B2 (ja) 2016-09-28
CN103200965B (zh) 2016-06-08
RU2013115923A (ru) 2014-10-20
BR112013004440A2 (pt) 2016-05-31

Similar Documents

Publication Publication Date Title
MX2013002725A (es) Metodo para atenuar los efectos adversos del farmaco usando los acidos grasos omega-3 como un vehiculo terapeutico parenteral del farmaco.
EP4338805A3 (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
SG10201809638YA (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
EP3143997A3 (en) Methods of administering pirfenidone therapy
WO2014004861A3 (en) Methods of treating pediatric metabolic syndrome
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
TN2014000001A1 (en) A new therapeutical composition containing apomorphine as active ingredient
GB2489382A (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
NZ630385A (en) Beta-hydroxy-beta-methylbutyric acid for improving glucose tolerance
EP2563350A4 (en) THERAPEUTIC REGIME AND METHOD FOR THE TREATMENT OR IMPROVEMENT OF VIEW DISORDERS ASSOCIATED WITH ENDOGENOUS RETINOID DEFICIENCY
WO2011143271A3 (en) Therapeutic liposomes and methods for producing and using the same
MX355388B (es) Composiciones farmaceuticas y metodos terapeuticos que emplean una combinacion de un compuesto complejo de manganeso y una forma compleja no de manganeso del compuesto.
IN2014CN04009A (es)
WO2012112862A3 (en) Treating mycobacterial infection with cu+/++ boosting therapeutics
WO2011026193A8 (en) Cytotoxic compounds
UA65038U (ru) Способ лечения больных послеродовыми психозами
UA53780U (ru) Способ лечения стеатоза печени у больных туберкулезом
UA69269U (ru) Способ лечения дисбактериоза у больных герпетическим стоматитом
UA69686U (ru) Способ профилактики обострений параноидной шизофрении
UA69222U (ru) Способ рефлексотерапии больных с отдаленными последствиями черепно-мозговой травмы
UA59176U (ru) Способ лечения больных стеатоза печени, соединенного с хроническим некалькулезным холециститом
MY184940A (en) Lignosus rhinocerus (tiger-milk mushroom) as anti-inflammatory agent
UA69863U (ru) Способ коррекции возрастных изменений кожи у женщин
NZ718896A (en) Methods for improving diaphragm function